BVXV Stock Price, News & Analysis

bvxv

Company Description

BVXV (Nasdaq: bvxv) is a publicly traded company.

bvxv stock has declined 22.8% over the past year.

This page provides a comprehensive overview of bvxv stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-22.81%

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

BVXV (bvxv) stock. Over the past 12 months, the stock has lost 22.8%.

Latest News

View All

April 10, 2024

—

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

March 12, 2024

—

Scinai leadership to attend BIO-Europe Spring 2024

conferences

February 13, 2024

—

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

January 4, 2024

—

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

offering

November 20, 2023

—

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

September 6, 2023

+3.82%

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

BVXV has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 4 with negative movement. Key topics include conferences, offering, earnings. View all bvxv news →

SEC Filings

View All

No SEC filings available for bvxv.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months